Delivery Order SPE2DB24D9113-SPE2DB25FEPVW

Award Date 1/31/25
Potential Completion Date 2/24/25
Potential Value $2.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order worth $2,082.93 awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract provides NEXPLANON 68 MG IMPLANTS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the issuance of delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,858.76, is for the delivery of NEXPLANON 68 MG IMPLANTS to support the medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which covers...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order worth $2,777.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of NEXPLANON 68 MG IMPLANTS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC covers a wide range of pharmaceutical products, including branded and generic...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,144.07, is for the delivery of NEXPLANON 68 MG IMPLANTS, a prescription contraceptive device, with a completion date of January 2, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $3,573.45 award is for the delivery of NEXPLANON 68 MG IMPLANTS, a contraceptive medical device, with a completion date of June 6, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $7,146.90 and covers the delivery of NEXPLANON 68 MG IMPLANTS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC enables the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $7,146.90, is for the delivery of NEXPLANON 68 MG IMPLANTS to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $2,777.24, is for the procurement of 4567193019 NEXPLANON 68 MG IMPLANTS. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group Inc. valued at $499,999,999, which enables the DLA to issue delivery orders...
This is a Firm Fixed Price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $3,573.45, is for the delivery of Nexplanon 68 mg implants. The contract is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued up to $499,999,999, which allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical items...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,943.10 firm fixed-price contract is for the delivery of NEXPLANON 68 MG IMPLANTS and is set to expire on February 4, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the issuance of delivery orders for a...
  • SPE2DB24D9113
    Indefinite Delivery Contract
  • SPE2DB24D9113-SPE2DB25FEPVW
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,777.24, is for the delivery of NEXPLANON 68 MG IMPLANTS to support the medical supply needs of military healthcare facilities.

DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This delivery order is not associated with a set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains. The contract has an ultimate completion date of February 24, 2025.

Generated 5/4/25, 12:56 AM